Adjuvant imatinib therapy for gastrointestinal stromal tumors

Peter W T Pisters, Chiara Colombo

Research output: Contribution to journalArticlepeer-review


Surgery is the standard of care for primary resectable gastrointestinal stromal tumors (GISTs), but half of surgically treated patients relapse. Imatinib (IM) has been shown to prolong recurrence-free survival after complete surgery and is now approved as adjuvant therapy (400 mg/day) for high-risk GIST patients. IM is well tolerated, with mild to moderate side effects observed. Whether adjuvant IM prolongs overall survival is under evaluation in two ongoing clinical trials. J. Surg. Oncol. 2011; 104:896-900.

Original languageEnglish
Pages (from-to)896-900
Number of pages5
JournalJournal of Surgical Oncology
Issue number8
Publication statusPublished - Dec 2011


  • adjuvant therapy
  • adverse events
  • gastrointestinal stromal tumor
  • GIST
  • imatinib
  • risk stratification

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Adjuvant imatinib therapy for gastrointestinal stromal tumors'. Together they form a unique fingerprint.

Cite this